Kadmon Holdings, Inc.’s $113 Million Follow-on Offering of Common Stock


Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock, which included the full exercise of the underwriters’ option to purchase additional shares of common stock.

The offering included an underwritten offering and a registered direct offering to certain institutional investors. The closing of an additional 2,280,302 shares of common stock in the registered direct offering is expected to occur on or about June 26, 2018.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. Its product pipeline is focused on inflammatory and fibrotic

diseases.

The Davis Polk corporate team included partners Michael Kaplan (Picture) and Sophia Hudson and associates Stephen A. Byeff, Angela Park and Young-Min Cho. The tax team included partner Rachel D. Kleinberg and associate Karen Li. The intellectual property and technology team included counsel David R. Bauer and associate Bonnie Chen. Associate Sijia Cai provided 1940 Act advice.

Involved fees earner: Michael Kaplan – Davis Polk & Wardwell; Sophia Hudson – Davis Polk & Wardwell; Stephen Byeff – Davis Polk & Wardwell; Angela Park – Davis Polk & Wardwell; Young-Min Cho – Davis Polk & Wardwell; Rachel Kleinberg – Davis Polk & Wardwell; Karen Li – Davis Polk & Wardwell; David Bauer – Davis Polk & Wardwell; Bonnie Chen – Davis Polk & Wardwell; Sijia Cai – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Kadmon Holdings Inc.;

Author: Ambrogio Visconti